Farhad Ravandi

Research interests

Publications

• Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-022-02103-8

• De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017

  Cancer · 2021 · https://doi.org/10.1002/cncr.33458

• Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.03736

• 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

  Blood · 2021 · https://doi.org/10.1182/blood.2021013626

• Acute myeloid leukemia: current progress and future directions

  Blood Cancer Journal · 2021 · https://doi.org/10.1038/s41408-021-00425-3

• Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

  Nature Communications · 2020 · 10.1038/s41467-020-19119-8

• Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

  Blood · 2020 · https://doi.org/10.1182/blood.2020007732

• Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

  Cancer Discovery · 2020 · 10.1158/2159-8290.cd-19-1011

• Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia

  JAMA Oncology · 2020 · 10.1001/jamaoncol.2020.4600

• Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2004444

• 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

  The Lancet Haematology · 2020 · https://doi.org/10.1016/s2352-3026(20)30210-6

• Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2019 · 10.6004/jnccn.2019.0028

• Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

  Blood · 2019 · https://doi.org/10.1182/blood-2019-01-894980

• Clinical experience with the BCL 2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

  American Journal of Hematology · 2017 · https://doi.org/10.1002/ajh.25000

• Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

  Journal of the National Comprehensive Cancer Network · 2017 · 10.6004/jnccn.2017.0116

• Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

  Blood · 2016 · https://doi.org/10.1182/blood-2016-01-689422

• Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30626-x

• Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

  Blood · 2016 · https://doi.org/10.1182/blood-2016-07-726588

• Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype

  Blood · 2016 · https://doi.org/10.1182/blood-2015-08-661702

• Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

  The Lancet Haematology · 2015 · https://doi.org/10.1016/s2352-3026(15)00048-4

• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

  Blood · 2013 · 10.1182/blood-2013-01-480228

• An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic Leukemia

  Cancer Cell · 2012 · https://doi.org/10.1016/j.ccr.2012.10.007

• Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.9429

• Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(11)70386-2

• Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2011.35.7525

• Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

  Blood · 2011 · https://doi.org/10.1182/blood-2010-08-301796

• Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.9456

• Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

  Blood · 2010 · https://doi.org/10.1182/blood-2010-03-276485

• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  Cancer · 2008 · 10.1002/cncr.23697

• Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2008.18.6130

• Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

  Blood · 2007 · 10.1182/blood-2007-03-078576

• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

  Blood · 2006 · https://doi.org/10.1182/blood-2006-05-021162

• Decitabine improves patient outcomes in myelodysplastic syndromes

  Cancer · 2006 · https://doi.org/10.1002/cncr.21792

• Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia

  Blood · 2006 · https://doi.org/10.1182/blood-2006-03-009142

Current projects

No projects listed.